GlassScriptPhysician profile
Miho Suga
NPI 1194175513
$5,502.79
in general payments reported to CMS, 2019-2025
24 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.53 · 2020: $445 · 2021: $397 · 2022: $633 · 2023: $1,780 · 2024: $2,048 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,973.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,001.78 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $927.63 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $905.31 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $409.92 | 2020-2025 | Krystexxa, Evenity, Prolia |
| Abbvie INC. | $397.97 | 2023-2025 | Vraylar, Ubrelvy |
| Abbott Laboratories | $292.45 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $249.61 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $215.37 | 2021-2024 | |
| Xeris Pharmaceuticals, INC. | $187.28 | 2023-2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $169.99 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.89 | 2022-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $111.71 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $79.00 | 2024 | Veozah |
| Mylan Specialty L.P. | $72.91 | 2024 | Yupelri |
| Intra-Sana Laboratories | $70.20 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $53.23 | 2021-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2023-2024 | Jardiance |
| Eisai INC. | $36.90 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $31.47 | 2024 | Quviviq |
| Ossur Americas, INC. | $21.36 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.35 | 2025 | Caplyta |
| Adlon Therapeutics L.P. | $18.60 | 2020 | |
| Horizon Therapeutics Plc | $17.76 | 2023 | Krystexxa |
| Apollo Endosurgery US INC | $7.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miho Suga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.